

# American Society of Hematology Annual Meeting (ASH) 2018

## Studies from US Oncology Research and The US Oncology Network

*San Diego Convention Center, San Diego, CA  
December 1-4, 2018*

### Poster Presentations

Authors	Title	Session #	Date/Time/Location
<b>Jeff Sharman</b> , Jacqueline C. Barrientos, Danielle M. Brander, John M. Pagel, Meghan Gutierrez, Karen Kadish, Brian Tomlinson, Nilanjan Ghosh, Nick Giasfis, David Ipe, Sandhya Upasani, Murali Sundaram, Lucille Ferrante, Carlos Amaya-Chanaga, Reethi Iyengar, and Anthony R. Mato	Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLL™ Real-World Registry	642 Abstract # 1872 USOR # 15005	Saturday, Dec. 1, 6:15 PM to 8:15 PM Hall GH San Diego Convention Center
Anthony R. Mato, Jacqueline C. Barrientos, Danielle M. Brander, John M. Pagel, Meghan Gutierrez, Karen Kadish, Brian Tomlinson, Nilanjan Ghosh, Nick Giasfis, David Ipe, Sandhya Upasani, Murali Sundaram, Lucille Ferrante, Carlos Amaya-Chanaga, Reethi Iyengar and <b>Jeff Sharman</b>	Prognostic Testing and Treatment Approaches in Patients with Chronic Lymphocytic Leukemia: Clinical Experience from an Interim Analysis of the informCLL™ Real-World Registry	642 Abstract # 1872 USOR # 15005	Saturday, Dec. 1, 6:15 PM to 8:15 PM Hall GH San Diego Convention Center
Loretta J. Nastoupil, Fontanet Bijou, Vincent Ribrag, Julio C. Chavez, Thomas E. Witzig, <b>David J. Andorsky, Leonard M. Klein, Daniel Greenwald</b> , Armando Santoro, Paolo Corradini, Ian W. Flinn, Randeep Sangha, Vaishalee P. Kenkre, Shailaja Uttamsingh, Patrick R. Hagner, Anita K. Gandhi, Tianlei Chen, Kristen Hege, Michael Pourdehnad and John Kuruvilla	Avadomide (CC-122), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma	623 Abstract # 1602 USOR # 13092	Saturday, Dec. 1, 6:15 PM to 8:15 PM Hall GH San Diego Convention Center
Roman Hajek, Evangelos Terpos, Hans C. Lee, Ajai Chari, Caitlin L. Costello, Noemi Puig, Xavier Leleu, Jesus G. Berdeja, Faith E. Davies, Katja Weisel, Saad Z. Usmani, Vania T. M. Hungria, Mario Boccadoro, <b>Robert M. Rifkin</b> , Jeffrey A. Zonder, Gordon Cook, Lucie Brožová, Magda Bařinová, Kaili Ren, Roxanne Cacioppo, Tomas Skacel, Dawn Marie Stull and Vladimir Maisnar	Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) – Effectiveness in Routine Clinical Practice Is Similar to the Efficacy in the Phase 3 Tourmaline-MM1 Trial: A Pooled Analysis from the Insight MM Observational Study and the Czech Registry of Monoclonal Gammopathies (RMG)	653 Abstract # 1971 USOR # 16035	Saturday, Dec. 1, 6:15 PM to 8:15 PM Hall GH San Diego Convention Center

## Poster Presentations

Authors	Title	Session #	Date/Time/Location
Anas Younes, <b>John M. Burke</b> , Bruce Cheson, Catherine Diefenbach, Silvia Ferrari, Uwe Hahn, Eliza Hawkes, Cyrus Khan, Izidore S. Lossos, Gerardo Musuraka, Monica Tani, Umberto Vitolo, Sam Yuen, Mikkel Z Oestergaard, Surya Chitra, Michael Wenger, Tina Nielsen, Gila Sellam and <b>Jeff Sharman</b>	Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study	626 Abstract # 2969 USOR # 15054	Sunday, Dec. 2, 6:00 PM to 8:00 PM Hall GH San Diego Convention Center
John C. Byrd, Richard R. Furman, Steven Coutre, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, <b>Jeff Sharman</b> , William G. Wierda, Weiqiang Zhao, Nyla A. Heerema, Ying Luan, Emily A. Liu, James P. Dean and Susan M. O'Brien	Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	642 Abstract # 3133 USOR # 10086	Sunday, Dec. 2, 6:00 PM to 8:00 PM Hall GH San Diego Convention Center
Saad Z. Usmani, Vania T. M. Hungria, Xavier Leleu, Hans C. Lee, Faith E. Davies, Caitlin L. Costello, <b>Robert M. Rifkin</b> , Katja Weisel, Ajai Chari, Noemi Puig, Mario Boccadoro, Gordon Cook, Jesus G. Berdeja, Jeffrey A. Zonder, Michael A. Thompson, Rafat Abonour, Jorge Vela-Ojeda, Roman Hajek, Andrew Spencer, Jim Omel, Brittany Demers, Dorothy Romanus, Kaili Ren, Tomas Skacel, Dawn Marie Stull and Evangelos Terpos	Transplant Status Does Not Impact the Selection of Induction Regimens for Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Insight MM Prospective, Observational Study	653 Abstract # 3289 USOR # 16035	Sunday, Dec. 2, 6:00 PM to 8:00 PM Hall GH San Diego Convention Center
Sundar Jagannath, Mohit Narang, Sikander Ailawadhi, <b>Robert M. Rifkin</b> , Howard R. Terebello, Kathleen Toomey, Brian GM Durie, James W. Hardin, Cristina J. Gasparetto, Lynne Wagner, James Omel, Shankar Srinivasan, Amani Kitali, Amit Agarwal, and Rafat Abonour	Treatment Choices and Outcomes for Patients with Multiple Myeloma after Relapse on Lenalidomide Maintenance Therapy: Results from the Connect <sup>®</sup> MM Registry	653 Abstract # 3232 USOR # 09141	Sunday, Dec. 2, 6:00 PM to 8:00 PM Hall GH San Diego Convention Center
Ravi Vij, Clara Chen, <b>Christopher A. Yasenckak</b> , Catherine Davis and David J. Kuter	Treatment Sequencing in Patients with Relapsed/Refractory Multiple Myeloma after Daratumumab Treatment: Real-World Findings from a Pooled Data Analysis of Preamble and the Mckesson Electronic Medical Record Database	653 Abstract # 3284 USOR # 12108	Sunday, Dec. 2, 6:00 PM to 8:00 PM Hall GH San Diego Convention Center
Jacob D. Soumerai, Mohamed Darif, Anil Londhe, Guan Xing, Yong Mun, Neil E. Kay, Tait D. Shanafelt, Kari G. Chaffee, Richard R. Furman, Peter Hillmen, <b>Jeff Sharman</b> , John F. Seymour, Asher A. Chanan-Khan, John C. Byrd, Jeffrey A. Jones, Lucille A. Ferrante, Lyndah K. Dreiling, Mehrdad Mobasher, Thomas Stark, Vijay Reddy, Angela J. Howes, Danelle James, Pankaj Bhargava, Andrew D. Zelenetz	Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy	641 Abstract # 4394 USOR # 11235, 12017	Monday, Dec. 3, 6:00 PM to 8:00 PM Hall GH San Diego Convention Center
Gilles Andre Salles, Wojciech Jurczak, <b>David J. Andorsky</b> , Donald P. Quick, Jack W. Singer, Simran Bedi Singh, Lixia Wang, Anton Egorov, Christine Gabarroca and Ruth Pettengell	Results of a Phase 3 Randomised Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation	626 Abstract # 4189 USOR # 10215	Monday, Dec. 3, 6:00 PM to 8:00 PM Hall GH San Diego Convention Center
Abdulraheem Yacoub, Srdan Verstovsek, Ryan Shao, David Tin Chu, Apurv Agrawal, Smitha Sivaraman, Philomena Colucci, Peter Yao and John Mascarenhas	Disease and Clinical Characteristics of Patients with Essential Thrombocythemia Enrolled in the MOST Study	634 Abstract # 4306 USOR # 16092	Monday, Dec. 3, 6:00 PM to 8:00 PM Hall GH San Diego Convention Center

## Poster Presentations (HEOR)

Authors	Title	Session #	Date/Time/Location
<b>Robert M. Rifkin</b> , David Singer, Kathleen M. Aguilar, Bismark Baidoo and Eric M Maiese	Safety of Split First Dosing Vs Standard Dosing Administration of Daratumumab Among Multiple Myeloma Patients Treated in a US Community Oncology Setting: A Real-World Observational Study	904 Abstract # 4846	Monday, Dec. 3, 6:00 PM to 8:00 PM Hall GH San Diego Convention Center
<b>Jeff Sharman</b> , Shaum Kabadi, Jamyia Clark, E Susan Amirian and <b>David J. Andorsky</b>	Treatment Patterns and Outcomes of 159 Ibrutinib-Treated MCL Patients in the United States: A Retrospective Electronic Medical Record Database and Chart Review Study	623 Abstract # 4163	Monday, Dec. 3, 6:00 PM to 8:00 PM Hall GH San Diego Convention Center

## Oral Presentations

Authors	Title	Session #	Date/Time/Location
<b>Habte A. Yimer</b> , <b>Jason Melear</b> , Edward Faber, William Bensinger, <b>John M. Burke</b> , <b>Mohit Narang</b> , Don Stevens, Sriya W. Gunawardena, Yana Lutska, Keqin Qi, Jon Ukropec, Ming Qi, Thomas Lin and <b>Robert M. Rifkin</b>	A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)	653 Abstract # 152 USOR # 16084	Saturday, Dec. 1, 12:15 PM Grand Ballroom 7 Marriott Marquis San Diego Marina
<b>Jeff Sharman</b> , Anna Marina Liberati, Rodrigo Santucci Silva, Igor Aurer, Jeffery Robbins, Julie Ann Rosenberg, Tahira Khan and Ann Alcasid	A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL)	623 Abstract # 394 USOR # 14020	Sunday, Dec. 2, 12:45 PM Ballroom 20A San Diego Convention Center

**Bolded text:** US Oncology Research affiliated investigator

***Learn More:***

**Online:** [usoncology.com/research](http://usoncology.com/research)

**Email:** [researchopportunities@mckesson.com](mailto:researchopportunities@mckesson.com)

**Phone:** (281) 863-1000

US Oncology Research and The US Oncology Network  
are supported by McKesson.

Copyright ©2018 McKesson. All rights reserved.

---

**MCKESSON**

